PureTech Health Financials

PRTC Stock  USD 16.64  0.35  2.06%   
PureTech Health PLC may be sliding down financialy. It has an above-average odds of going through some form of financial crisis next quarter. At present, PureTech Health's Property Plant And Equipment Net is projected to increase significantly based on the last few years of reporting. The current year's Accounts Payable is expected to grow to about 8 M, whereas Total Assets are forecasted to decline to about 554 M. Key indicators impacting PureTech Health's financial strength include:
Current ValueLast YearChange From Last Year 10 Year Trend
Current Ratio8.828.4
Sufficiently Up
Slightly volatile
The essential information of the day-to-day investment outlook for PureTech Health includes many different criteria found on its balance sheet. An individual investor should monitor PureTech Health's cash flow, debt, and profitability to accurately make informed decisions on whether to invest in PureTech Health.

Net Income

64.61 Million

  
Build AI portfolio with PureTech Stock
Please note, the presentation of PureTech Health's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, PureTech Health's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of PureTech Health's management manipulating its earnings.

PureTech Health Stock Summary

PureTech Health competes with Autolus Therapeutics, Neurogene, Solid Biosciences, QuantumSi, and Lineage Cell. PureTech Health plc, a clinical-stage biotherapeutics company, discovers, develops, and commercializes medicines for inflammatory, fibrotic and immunological, intractable cancers, lymphatic and gastrointestinal, neurological and neuropsychological, and other diseases in the United States. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts. PureTech Health operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 95 people.
Foreign Associate
  UK
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
InstrumentUSA Stock View All
ExchangeNASDAQ Exchange
ISINUS7462371060
Business Address6 Tide Street,
SectorBiotechnology
IndustryHealth Care
BenchmarkDow Jones Industrial
Websitewww.puretechhealth.com
Phone617 482 2333
CurrencyUSD - US Dollar

PureTech Health Key Financial Ratios

PureTech Health Key Balance Sheet Accounts

202120222023202420252026 (projected)
Total Assets946.0M702.6M694.0M602.6M693.0M554.0M
Other Current Liab174.0M55.7M59.1M28.1M32.3M30.7M
Net Debt(413.7M)(103.0M)(165.7M)(258.3M)(232.5M)(244.1M)
Retained Earnings199.9M149.5M83.8M32.5M37.4M23.4M
Accounts Payable11.3M26.5M14.6M5.5M6.4M8.0M
Cash465.7M149.9M191.1M280.6M322.7M190.2M
Net Receivables3.6M22.4M2.4M12.9M14.8M15.6M
Other Current Assets4.5M13.7M17.7M6.0M7.0M7.0M
Total Liab361.9M155.1M235.7M194.7M223.9M223.0M
Total Current Assets501.8M386.2M347.2M386.3M444.2M297.7M
Short Term Debt9.4M12.5M7.1M7.7M8.8M9.3M
Intangible Assets987K831K906K601K540.9K513.9K
Common Stock5.4M5.5M5.5M4.9M4.4M4.2M
Other Liab116.7M108.6M92.4M23.8M27.3M26.0M
Net Tangible Assets667.4M668.8M592.5M541.4M622.6M490.8M
Other Assets2.3M1K2.1M1.00.90.86
Short Long Term Debt4.8M7.5M3.7M4.1M3.7M6.6M
Net Invested Capital612.5M560.0M467.8M418.8M481.6M543.0M
Net Working Capital275.7M289.3M295.8M344.9M396.6M416.4M
Capital Stock5.4M5.5M5.5M4.9M4.4M4.3M

PureTech Health Key Income Statement Accounts

202120222023202420252026 (projected)
Interest Expense4.7M4.0M13.5M10.0M11.5M6.7M
Total Revenue10.0M2.1M3.3M4.8M4.3M5.4M
Gross Profit(100.5M)(136.8M)(1.6M)1.3M1.1M1.2M
Operating Income(150.3M)(197.8M)(146.2M)(136.1M)(122.5M)(128.6M)
Ebit19.5M(197.8M)(16.6M)33.8M38.9M40.8M
Research Development81.5M116.1M96.2M54.3M62.4M56.5M
Ebitda26.7M(188.9M)(11.6M)37.4M43.0M45.1M
Income Before Tax(59.0M)(92.8M)(36.1M)23.8M27.3M28.7M
Net Income(60.6M)(50.4M)(65.7M)53.5M61.5M64.6M
Income Tax Expense3.8M(55.7M)30.5M(4.0M)(4.6M)(4.4M)
Tax Provision3.8M(55.7M)30.5M(4.0M)(3.6M)(3.4M)
Net Interest Income(4.5M)1.8M2.5M12.6M14.5M15.3M
Interest Income214K5.8M16.0M22.7M26.1M27.4M
Minority Interest2.2M(13.3M)931K25.7M29.6M31.1M

PureTech Health Key Cash Accounts

202120222023202420252026 (projected)
Change In Cash61.8M(315.8M)41.2M89.6M80.6M84.6M
Free Cash Flow(163.9M)(181.0M)(106.2M)(134.4M)(120.9M)(127.0M)
Depreciation7.3M8.9M4.9M3.6M4.1M3.9M
Other Non Cash Items(5.1M)(111.1M)(67.1M)(178.3M)(160.5M)(152.5M)
Capital Expenditures5.7M2.2M245K11K12.7K12.0K
Net Income(62.7M)(37.1M)(65.7M)27.8M31.9M33.5M
End Period Cash Flow465.7M149.9M191.1M280.6M322.7M176.9M
Investments217.6M(107.2M)69.0M240.9M277.0M290.9M

PureTech Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining PureTech Health's current stock value. Our valuation model uses many indicators to compare PureTech Health value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across PureTech Health competition to find correlations between indicators driving PureTech Health's intrinsic value. More Info.
PureTech Health PLC is considered to be number one stock in return on equity category among its peers. It also is considered to be number one stock in return on asset category among its peers . At present, PureTech Health's Return On Equity is projected to increase slightly based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the PureTech Health's earnings, one of the primary drivers of an investment's value.

PureTech Health PLC Systematic Risk

PureTech Health's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. PureTech Health volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was thirty with a total number of output elements of thirty-one. The Beta measures systematic risk based on how returns on PureTech Health PLC correlated with the market. If Beta is less than 0 PureTech Health generally moves in the opposite direction as compared to the market. If PureTech Health Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one PureTech Health PLC is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of PureTech Health is generally in the same direction as the market. If Beta > 1 PureTech Health moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in PureTech Health Stock are looking for potential investment opportunities by analyzing not only static indicators but also various PureTech Health's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of PureTech Health growth as a starting point in their analysis.

Price Earnings To Growth Ratio

(0.0613)

At present, PureTech Health's Price Earnings To Growth Ratio is projected to slightly decrease based on the last few years of reporting.

PureTech Health January 4, 2026 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of PureTech Health help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of PureTech Health PLC. We use our internally-developed statistical techniques to arrive at the intrinsic value of PureTech Health PLC based on widely used predictive technical indicators. In general, we focus on analyzing PureTech Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build PureTech Health's daily price indicators and compare them against related drivers.

Complementary Tools for PureTech Stock analysis

When running PureTech Health's price analysis, check to measure PureTech Health's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy PureTech Health is operating at the current time. Most of PureTech Health's value examination focuses on studying past and present price action to predict the probability of PureTech Health's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move PureTech Health's price. Additionally, you may evaluate how the addition of PureTech Health to your portfolios can decrease your overall portfolio volatility.
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Transaction History
View history of all your transactions and understand their impact on performance